Back to search results

Pan Tumor Rollover Study for Cancer Treatments

This study is looking at the long-term safety of several cancer treatments, including nivolumab, ipilimumab, cabozantinib, trametinib, and relatlimab, used alone or in combination, across different types of cancer. The main goal is to understand how often side effects (adverse events) happen, how many are related to the drugs, and how many lead to stopping treatment. You may be able to join if you are 18 or older, have already been in a 'Parent Study' for one of these treatments, and are eligible to continue or restart treatment based on that study. The study aims to enroll 1500 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 1500 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for side effects from Day 1 up to 135 days after stopping treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03899155

Pan Tumor Rollover Study

Recruiting
PHASE2Ages 18+InterventionalTreatment
Bristol-Myers Squibb
~1,500 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:NivolumabIpilimumabCabozantinibTrametinibRelatlimabNivolumab + Relatlimab

At a glance

Recruiting sites
109 of 399 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Adverse Events (AEs)
Measured over From Day 1 up to 135 Days after discontinuation of treatment
+6 more outcomes measured

Conditions

Cancer

Explore related trials

Solid Neoplasm

NCT03899155

Where you'd take part

This study runs at 399 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • "Azienda Ospedaliero - Universitaria ""Policlinico-Vittorio Emanuele"" - Ospedale Gaspare Rodolico"

    Catania, Italystudy coordinator listed

    Recruiting

  • Alexandra Hospital

    Athens, Attica, Greecestudy coordinator listed

    Recruiting

  • APHM - Hopital de la Timone

    Marseille, Francestudy coordinator listed

    Recruiting

  • Asan Medical Center

    Seoul, Songpa-gu, South Koreastudy coordinator listed

    Recruiting

  • Auckland City Hospital

    Auckland, New Zealandstudy coordinator listed

    Recruiting

  • Azienda Ospedaliera Citta della Salute e della Scienza

    Torino, Italystudy coordinator listed

    Recruiting

  • Cabrini Hospital Malvern

    Malvern, Victoria, Australiastudy coordinator listed

    Recruiting

  • CAIPO Centro para la Atencion Integral del Paciente Oncologico

    San Miguel de Tucumán, Tucumán Province, Argentinastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Signed Written Informed Consent.
Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.
On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.
WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.

Exclusion

Participant is not eligible for study treatment per the Parent Study eligibility criteria.
Participants not receiving clinical benefit as assessed by the Investigator.
Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.

What this trial measures

  • Incidence of Adverse Events (AEs)From Day 1 up to 135 Days after discontinuation of treatment
  • Incidence of drug related AEsFrom Day 1 up to 135 Days after discontinuation of treatment
  • Incidence of AEs leading to DiscontinuationFrom Day 1 up to 135 Days after discontinuation of treatment
  • Incidence of Serious Adverse Events (SAEs)From signature of Informed Consent up to 135 Days after discontinuation of treatment
  • Incidence of Select AEsFrom Day 1 up to 135 Days after discontinuation of treatment
  • Incidence of Immune-Mediated AEsFrom Day 1 up to 135 Days after discontinuation of treatment
  • Incidence of DeathFrom signature of Informed Consent up to 135 Days after discontinuation of treatment